Home > Publications > CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B
Publications

CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B

Bibliography:

Mustapha Aouida, Ayman Eid, Magdy M. Mahfouz​. CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B. Biochimie Open. doi:10.1016/j.biopen.2016.02.001​

Authors:

Mustapha Aouida, Ayman Eid, Magdy M. Mahfouz

Keywords:

CRIPSR/Cas9, Pladienolide B, Spliceosome, Pre-mRNA splicing, Drug target validation, Drug discovery

Year:

2015

Abstract:

CRISPR/Cas9 system confers molecular immunity in archeal and bacterial species against invading foreign nucleic acids. CRISPR/Cas9 system is used for genome engineering applications across diverse eukaryotic species. In this study, we demonstrate the utility of the CRISPR/Cas9 genome engineering system for drug target validation in human cells. Pladienolide B is a natural macrolide with antitumor activities mediated through the inhibition of pre-mRNA splicing. To validate the spliceosomal target of Pladienolide B, we employed the CRSIPR/Cas9 system to introduce targeted mutations in the subunits of the SF3B complex in the HEK293T cells. Our data reveal that targeted mutagenesis of the SF3b1 subunit exhibited higher levels of resistance to Pladienolide B. Therefore, our data validate the spliceosomal target of Pladienolide B and provide a proof of concept on using the CRISPR/Cas9 system for drug target identification and validation.

ISSN:

2214-0085